Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 9,627 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo (in-patient) Clear all

Conditions: Ulcerative Colitis
Interventions: RO7837195, RO7837195 Matched Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Lancaster, California • San Diego, California • Colorado Springs, Colorado + 6 more

Conditions: Snake Bite
Interventions: Crotalinae (pit viper) equine immune F(ab)2, Crotalidae Polyvalent Immune Fab, ovine; Biological
Lead sponsor: Instituto Bioclon S.A. de C.V.; Industry
Eligibility: 2 Years to 80 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 10 more

Conditions: Colorectal Cancer
Interventions: Vandetanib, FOLFIRI; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Ann Arbor, Michigan • New York, New York • Nashville, Tennessee + 1 more

Conditions: Cancer, Remission
Interventions: Tibetree Pain Relieving Plaster, Placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Type 2 Diabetes Mellitus
Interventions: LIK066, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Cognitive Impairment
Interventions: Aricept; Drug
Lead sponsor: Eisai Limited; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Maywood, Illinois • New York, New York

Conditions: Covid19
Interventions: Telmisartan Oral Product, Placebo; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Brain Neoplasms
Interventions: Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo; Drug · Radiation · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Cognitive Side Effects of Cancer Therapy, Depression, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions: typhoid vaccine, Placebo; Biological · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 35 Years to 80 Years · Female only
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide SAR439977, Placebo, Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more

Conditions: Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Interventions: Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Doxorubicin-Eluting Beads, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Mitomycin, Pharmacological Study, Placebo Administration, Sorafenib Tosylate; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 281
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 183 more

Conditions: Intermittent Claudication
Interventions: ataciguat (HMR1766), placebo, cilostazol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years and older
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Breast Cancer
Interventions: Cobimetinib, Paclitaxel, Placebo, Atezolizumab, Nab-Paclitaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 11
States / cities: Jacksonville, Florida • Miami, Florida • Orlando, Florida + 8 more

Conditions: Breast Cancer
Interventions: 'R' (Electro-kinetically altered beverage), Placebo (water); Other
Lead sponsor: South Sound Care Foundation; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 6
States / cities: Bonney Lake, Washington • Federal Way, Washington • Gig Harbor, Washington + 3 more

Conditions: Covid-19
Interventions: Octagam 10%, Saline Solution; Biological · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Sheffield, Alabama • Loma Linda, California • Newport Beach, California + 11 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: anamorelin HCl, placebo; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Little Rock, Arkansas • Melbourne, Florida • Augusta, Georgia + 12 more

Conditions: Parkinson Disease
Interventions: sumanirole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 60 more

Conditions: Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions: Atorvastatin and Lisinopril, Placebo; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Long QT Syndrome Type 3
Interventions: Eleclazine, Eleclazine placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Rochester, Minnesota • New York, New York • Rochester, New York

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Orelabrutinib, Placebo; Drug
Lead sponsor: Zenas BioPharma (USA), LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 27
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 23 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Vilazodone; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 52
States / cities: Imperial, California • Los Angeles, California • Murrieta, California + 46 more

Conditions: Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
Interventions: Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Placebo Administration, Sargramostim; Drug · Other · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 12
States / cities: Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more

Conditions: Thyroid; Functional Disturbance, Hypothyroidism, Hemodialysis
Interventions: Levothyroxine Sodium, Placebos; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Orange, California

Conditions: Covid19, SARS-CoV Infection
Interventions: Sargramostim, Placebo; Drug
Lead sponsor: Partner Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more

Search by objective public record fields.

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.

A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

Testing an Herbal Pain Relief Patch to Reduce Pain in Cancer Survivors

Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

INvestigating TELmisartin Study

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Effects of 'R' (Electro-kinetic Beverage) on Insomnia, Fatigue, and Depression in Breast Cancer Patients Having Adjuvant Chemo

Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

Sargramostim Use in COVID-19 to Recover Patient Health